Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts

Oncogene

Volumn 16, Issue 17, 1998, Pages 2287-2291

  Kilbey, Anna ^a   Bartholomew, Chris ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Evi 1; Leukaemogenesis; Transcriptional repression

Indexed keywords

REPRESSOR PROTEIN;

ARTICLE; DNA BINDING; DNA TRANSCRIPTION; FIBROBLAST; MYELOID LEUKEMIA; PRIORITY JOURNAL;

ANIMALIA;

EID: 0032580370     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1201732     Document Type: Article

References (24)

1. Bartholomew C and Clark AM. (1994). Oncogene, 9, 939-942.
2. Bartholomew C, Kilbey A, Clark AM and Walker M. (1997). Oncogene, 14, 569-577.
3. Bergeron D, Poliquin L, Houde J, Barbeau B and Rassart E. (1992). Virology, 191, 661-669.
4. Bordereaux D, Fichelson S, Tambourin P and Gisselbrecht S. (1990). Oncogene, 5, 925-927.
5. Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, Yang J-M, Guan X-Y, Trent J, Alberts DS and Taetle R. (1996). Br. J. Cancer, 74, 1518-1525.
6. Cowell IG. (1994). TIBS. 19, 38-42.
7. Delwel R, Funabiki T, Kreider BL, Morishita K and Ihle JN. (1993). Mol. Cell. Biol. 13, 4291-4300.
8. Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD and Nucifora G. (1996). Proc. Natl. Acad. Sci. USA, 93, 1642-1647.
9. Funabiki T, Kreider BL and Ihle JN. (1994). Oncogene, 9, 1575-1581.
10. Hollenberg SM, Sternglanz R, Cheng PF and Weintraub H. (1995). Mol. Cell. Biol., 15, 3813-3822.
11. Hoyt PR, Bartholomew C, Davis AJ, Yutzey K, Gamer LW, Potter SS, Ihle JN and Mucenski ML. (1997). Mech. Dev., 65, 55-70.
12. Kreider BL, Orkin SH and Ihle JN. (1993). Proc. Natl. Acad. Sci. USA, 90, 6454-6458.
13. Kurokawa M, Ogawa S, Tanaka T, Mitani K, Yazaki Y, Witte ON and Hirai H. (1995). Oncogene, 11, 833-840.
14. Licht JD, Ro M, English MA, Grossel M and Hansen U. (1993). Proc. Natl. Acad. Sci. USA, 90, 11361-11365.
15. Matsugi T, Morishita K, and Ihle JN. (1990). Mol. Cell. Biol., 10, 1259-1264.
16. Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, Mano H, Yazaki Y, Ohki M and Hirai H. (1994). EMBO. J., 13, 504-510.
17. Morishita K, Parganas E, Douglass EC and Ihle JN. (1990). Oncogene, 5, 963-971.
18. Morishita K, Parganas E, Matsugi T and Ihle JN. (1992b). Mol. Cell. Biol., 12, 183-189.
19. Morishita K, Parganas E, Willman CL, Whittaker MH, Drabkin H, Oval J, Taetle R, Valentine MB and Ihle JN. (1992a). Proc. Natl. Acad. Sci. USA, 89, 3937-3941.
20. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG and Ihle JN. (1988). Cell, 54, 831-840.
21. Ogawa S, Kurokawa M, Tanaka T, Mitani K, Inazawa J, Hangaishi A, Tanaka K, Matsuo Y, Minowda J, Tsubota T, Yazaki Y and Hirai H. (1996). Oncogene, 13, 183-191.
22. Shi Y, Seto E, Chang L-E and Shenk T. (1991). Cell, 67, 377-388.
23. Soderholm J, Kobayashi H, Mathieu C, Rowley JD and Nucifora G. (1997). Leukemia, 11, 352-358.
24. Suzukawa K, Taki T, Abe T, Asoh H, Kamada N, Yokota J and Morishita K. (1997). Genomics, 42, 356-360.